Table 2 Profiles of patients who developed HCC during entecavir treatment.

From: Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment

  1. The patients whose data are shaded gave serum samples 6 and 12 months after commencement of entecavir treatment, 6 and 12 months before HCC development, and at the time of HCC development.
  2. HCC, hepatocellular carcinoma; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; HBcrAg, hepatitis B core-related antigen; HBV, hepatitis B virus; AFP, α-fetoprotein; sPD-1, soluble programmed cell death-1.
Back to article page